Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Bristol Myers Squibb

Bristol Myers Stock: This Covered Call Could Enhance Your Return Beyond A 4% Dividend Yield

The sold call produces a 9.83% annualized yield in addition to the dividend.

Investors Business Daily

Inside the futuristic biotech startup Cellares that’s building a cure for cancer with $355 million in funding

Why New Jersey is a hub for biotech manufacturing.

Fortune

Bristol Myers Squibb Shows Market Leadership With Jump To 93 RS Rating

Bristol Myers Squibb shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Stocks To Watch: Bristol Myers Squibb Sees Relative Strength Rating Jump To 85

Bristol Myers Squibb sees its Relative Strength Rating enter the 80-plus level.

Investors Business Daily

People with blood cancer to benefit from innovative new treatment on the NHS

The type of Car T-cell therapy involves taking a patient’s T-cells and modifying them.

Evening Standard

Bristol Myers Wallops Fourth-Quarter Views, But Shares Slide On 2025 Outlook

Bristol Myers walloped sales views Thursday, but Bristol Myers Squibb stock took a hit on a light outlook hamstrung by generic competition.

Investors Business Daily

Analyst: Sell ‘Magnificent 7’ Stocks and Buy These 3 Dividend Stocks Instead

Analysts at Miramar Capital are advising investors to sell “Magnificent 7” and instead invest in lower-valuation, dividend-paying healthcare stocks.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Why This Dividend Stock Just Scored a Rare Upgrade

Bristol Myers Squibb, a global biopharma company, has received a rare upgrade from Jefferies due to its promising pipeline and strategic partnerships.

Barchart

Bristol Myers Squibb Stock Earns 83 RS Rating

Bristol Myers Squibb sees its Relative Strength Rating reach the 80-plus level.

Investors Business Daily

Bristol Myers Squibb Clears Key Benchmark, Hitting 80-Plus RS Rating

Bristol Myers Squibb shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 83.

Investors Business Daily

Bristol Myers Squibb Gets RS Rating Upgrade

Bristol Myers Squibb shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Bristol Rockets 11% As Investors Question AbbVie's $8.7 Billion 'Mistake'

Bristol Myers Squibb stock rocketed Monday after AbbVie's experimental schizophrenia treatment failed in a pair of midstage studies.

Investors Business Daily

Bristol Myers Squibb Trying To Close In On Key Technical Measure

Bristol Myers Squibb shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Bristol Myers Squibb Stock Gets Relative Strength Rating Upgrade

Bristol Myers Squibb shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Bristol Myers Screams To A Year-High After Walloping Profit Expectations

Bristol Myers Squibb walloped profit expectations in the September quarter, and Bristol Myers stock screamed to a year-high.

Investors Business Daily

Has Consumer Products Giant Bristol-Myers Squibb Kicked Into High Gear?

A Relative Strength Rating upgrade for Bristol Myers Squibb shows improving technical performance. Will it continue?

The Independent UK

New schizophrenia drug ‘could change the lives of millions of people’

The US Food and Drug Administration has approved Cobenfy, which is owned by pharmaceutical firm Bristol Myers Squibb.

Medical Daily

Cobenfy Gets FDA Approval: New Drug Offers Novel Treatment Mechanism For Schizophrenia

The new drug Cobenfy promises to revolutionize treatment for schizophrenia with its novel mechanism, the first of its kind in decades.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?

Pharmaceutical stocks largely shook off the brunt of negotiated drug prices. But that doesn't mean they'll be spared election noise.

Investors Business Daily

Bristol Myers Retakes Its 200-Day Line On Quarterly Beat, Surprise Immunology Win

Bristol Myers Squibb stock gapped higher Friday after the Big Pharma stalwart beat June-quarter forecasts and raised its outlook.

Investors Business Daily

Catalyst's New CEO Has Big Ideas For The Small Biotech

Richard Daly has watched Catalyst Pharmaceuticals transform. Now, as the company's new CEO, he has some metamorphic ideas of his own.

The Hindu

$100-million facility of Bristol Myers Squibb opened in Hyderabad

Bristol Myers Squibb opens new facility in Hyderabad, investing over $100 million to expand global capabilities.

Top News

Bristol Myers Squibb Reports Strong Q4 Results

Bristol Myers Squibb (BMY) reports strong Q4 results, faces biosimilar competition, but shows growth potential.

WEKU

Senators ask CEOs why their drugs cost so much more in the U.S.

The Senate HELP committee questioned pharmaceutical CEOs about how much more Americans pay for the same drugs sold for less in Canada, Japan and Europe.

Roll Call

Merck, Johnson & Johnson CEOs agree to appear before Senate HELP - Roll Call

Two drug company CEOs have agreed to testify before the Senate HELP Committee on drug prices, avoiding a scheduled subpoena vote on Jan. 31.

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

325 stories

Jefferies

313 stories

Investor Business Daily

the University of Oxford

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.